How have FRX shares performed in 2024?

Fennec Pharmaceuticals' stock was trading at C$15.16 at the beginning of the year. Since then, FRX stock has decreased by 9.2% and is now trading at C$13.77. View the best growth stocks for 2024 here .

When is Fennec Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our FRX earnings forecast .

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc. (TSE:FRX) announced its quarterly earnings results on Thursday, March, 21st. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.16. The biopharmaceutical company earned $13.25 million during the quarter, compared to analysts' expectations of $12.88 million. Fennec Pharmaceuticals had a negative net margin of 75.50% and a negative trailing twelve-month return on equity of 1,005.59%.

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Encanto Potash (EPO) , Acadian Timber (ADN) , Agellan Commercial Real Estate Invtmt TR (ACR.UN) , AutoCanada (ACQ) , ATCO (ACO.X) , Accord Financial (ACD) , Aurora Cannabis (ACB) , Air Canada (AC) and Barrick Gold (ABX) .

How do I buy shares of Fennec Pharmaceuticals?

Shares of FRX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

TSE:FRX

Fennec Pharmaceuticals (FRX) Stock Price, News & Analysis

→ Don’t expose yourself to stocks during the week (From DTI) (Ad)

Free FRX Stock Alerts

C$13.77

-0.55 (-3.84%)

(As of 04/17/2024 ET)

Compare

Today's Range: C$13.77
▼
C$13.77
50-Day Range: C$12.02
▼
C$15.20
52-Week Range: C$9.27
▼
C$15.43

Volume: 200 shs
Average Volume: 735 shs
Market Capitalization: C$372.34 million

P/E Ratio: N/A
Dividend Yield: 2.02%
Price Target: N/A

Stock Analysis Chart Competitors Earnings Headlines Insider Trades

Get Fennec Pharmaceuticals alerts:

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Fennec Pharmaceuticals Stock (TSE:FRX)

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

FRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FRX Stock News Headlines

April 17, 2024 | insidertrades.com

Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Adrian J. Haigh Acquires 22,222 Shares

March 31, 2024 | insidertrades.com

Chris Anigeron Rallis Sells 2,114 Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) Stock

April 19, 2024 | Tips4Traders (Ad)

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

April 5, 2024 | finance.yahoo.com

Insider Sell: CEO Rosty Raykov Sells 88,583 Shares of Fennec Pharmaceuticals Inc (FENC)

April 1, 2024 | seekingalpha.com

FRX:CA Fennec Pharmaceuticals Inc.

March 23, 2024 | seekingalpha.com

Fennec Pharmaceuticals Inc. (FENC) Q4 2023 Earnings Call Transcript

March 22, 2024 | finance.yahoo.com

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2023 Earnings Call Transcript

March 21, 2024 | finanznachrichten.de

Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update

April 19, 2024 | DTI (Ad)

Special FREE offer on stock hotsheets

These sheets tell you the exact day you should consider buying a stock… And the exact day you should consider selling it… All based on TEN YEARS of historic data and trends. For example, like January 6th through the 12th with Apple… It’s gone up every single year for the last decade. Or like May 26th through June 11th with LULU… Again - it’s gone up every single year for the last decade. Then there’s July 1st through the 21st with Walmart… What happened to WMT?

March 19, 2024 | ca.finance.yahoo.com

Stocks in play: Fennec Pharmaceuticals Inc.

March 17, 2024 | markets.businessinsider.com

Fennec, Norgine Reach Licensing Deal To Commercialize Pedmarqsi In Europe, Australia, & New Zealand

February 29, 2024 | finance.yahoo.com

Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

February 23, 2024 | finance.yahoo.com

FENC Mar 2024 10.000 call

February 1, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Societal CDMO (SCTL)

December 6, 2023 | finance.yahoo.com

With 31% stake, Fennec Pharmaceuticals Inc. (NASDAQ:FENC) seems to have captured hedge funds investors' interest

December 1, 2023 | morningstar.com

Fennec Pharmaceuticals Inc FRX

November 9, 2023 | seekingalpha.com

Fennec Pharmaceuticals Expands Possible TAM Significantly

November 9, 2023 | finance.yahoo.com

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

November 7, 2023 | finance.yahoo.com

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2023 Earnings Call Transcript

November 7, 2023 | finance.yahoo.com

Q3 2023 Fennec Pharmaceuticals Inc Earnings Call

November 3, 2023 | benzinga.com

Preview: Fennec Pharmaceuticals's Earnings

November 1, 2023 | finance.yahoo.com

Investors in Fennec Pharmaceuticals (NASDAQ:FENC) have unfortunately lost 20% over the last year

October 30, 2023 | finance.yahoo.com

Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023

October 5, 2023 | finance.yahoo.com

Analysts Expect Breakeven For Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Before Long

September 30, 2023 | theglobeandmail.com

Closing Bell: Fennec Pharmaceuticals Inc up on Friday (FRX)

August 23, 2023 | theglobeandmail.com

Fennec Pharmaceuticals: Top 10 Undervalued Healthcare Sector Stocks on TSX (FRX)

May 25, 2023 | theglobeandmail.com

Closing Bell: Fennec Pharmaceuticals Inc down on Wednesday (FRX)

See More Headlines

Receive FRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: TSE:FRX
CUSIP: N/A
CIK: N/A
Web: fennecpharma.com
Phone: +1-919-6364530
Fax: N/A
Employees: 29
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): C($1.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 32.77
P/E Growth: N/A
Net Income: C$-16,050,000.00
Net Margins: -75.50%
Pretax Margin: N/A
Return on Equity: -1,005.59%
Return on Assets: -29.67%

Debt

Debt-to-Equity Ratio: 881.09
Current Ratio: 3.29
Quick Ratio: 10.17

Sales & Book Value

Annual Sales: C$21.25 million
Price / Sales: 17.52
Cash Flow: C$1.18 per share
Price / Cash Flow: 11.66
Book Value: C($0.44) per share
Price / Book: -31.30

Miscellaneous

Outstanding Shares: 27,040,000
Free Float: N/A
Market Cap: C$372.34 million
Optionable: Not Optionable
Beta: 0.35

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Rostislav Raykov (Age 48)
CEO & Director
Comp: $1.22M
Mr. Robert C. Andrade (Age 49)
Chief Financial Officer
Comp: $826.82k
Mr. Adrian J. Haigh (Age 65)
Chief Operating Officer
Comp: $542.42k
Mr. Mark Gowland
Controller
Mr. Lei Fang
President of Pharstat Inc

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

FRX Stock Analysis - Frequently Asked Questions

How have FRX shares performed in 2024?: Fennec Pharmaceuticals' stock was trading at C$15.16 at the beginning of the year. Since then, FRX stock has decreased by 9.2% and is now trading at C$13.77.
View the best growth stocks for 2024 here.
When is Fennec Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our FRX earnings forecast.
How were Fennec Pharmaceuticals' earnings last quarter?: Fennec Pharmaceuticals Inc. (TSE:FRX) announced its quarterly earnings results on Thursday, March, 21st. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.16. The biopharmaceutical company earned $13.25 million during the quarter, compared to analysts' expectations of $12.88 million. Fennec Pharmaceuticals had a negative net margin of 75.50% and a negative trailing twelve-month return on equity of 1,005.59%.

What other stocks do shareholders of Fennec Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Encanto Potash (EPO), Acadian Timber (ADN), Agellan Commercial Real Estate Invtmt TR (ACR.UN), AutoCanada (ACQ), ATCO (ACO.X), Accord Financial (ACD), Aurora Cannabis (ACB), Air Canada (AC) and Barrick Gold (ABX).
How do I buy shares of Fennec Pharmaceuticals?: Shares of FRX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:FRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial